Are you interested in participating in a study by Asymmetrex to evaluate the current state of knowledge on the changing stem cell medicine landscape? If so, please, visit:

Go to the profile of James L. Sherley, M.D., Ph.D.
James L. Sherley, M.D., Ph.D. on Oct 21, 2019
• 0
The landscape of stem cell medicine is changing, and it’s all about counting. There is growing awareness of the long-standing unmet need for specific counting of therapeutic tissue stem cells. This year, the FDA’s Standards Coordinating Body (SCB) listed determination of tissue stem cell-specific dose as a priority for standards development for stem cell clinical trials.